Figure 2.
E2 regulates whole-body insulin sensitivity. (A) Average of glucose infusion rate during the last 40 minutes of euglycemic-hyperinsulinemic clamp. (B) Insulin-stimulated whole-body glucose uptake during the euglycemic-hyperinsulinemic clamp. (C) Basal endogenous glucose production. (D) Insulin-stimulated endogenous glucose production suppression during the euglycemic-hyperinsulinemic clamp. (E) Insulin-stimulated 2-DG uptake in skeletal muscle (Gastro). (F) Insulin-stimulated 2-DG uptake in WAT. (G) Insulin-stimulated AKT2 phosphorylation in liver. (H) Insulin-stimulated AKT2 phosphorylation in skeletal muscle (Gastro). (I) Insulin-stimulated AKT2 phosphorylation in WAT. Significance between groups was determined by 1-way ANOVA (n = 8). Data represent the mean ± SEM. GIR, glucose infusion rate; EGP, endogenous glucose production; gastro, gastrocnemius; AU, arbitrary units.